CJC-1295 vs GHK-Cu (Copper Peptide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
CJC-1295
CJC-1295 is a synthetic analog of growth hormone-releasing hormone (GHRH) that stimulates the pituitary gland to produce more growth hormone.
Full details →GHK-Cu (Copper Peptide)
GHK-Cu is a naturally occurring copper peptide found in human plasma, saliva, and urine. It plays important roles in wound healing, tissue repair, and has shown anti-aging properties in research.
Full details →Side-by-Side Comparison
| Aspect | CJC-1295 | GHK-Cu (Copper Peptide) |
|---|---|---|
| Mechanism | CJC-1295 binds to GHRH receptors in the pituitary, triggering increased production and release of growth hormone. The DAC (Drug Affinity Complex) version extends half-life significantly. | Attracts immune cells and fibroblasts to wound sites, stimulates collagen and glycosaminoglycan synthesis, promotes angiogenesis, and has antioxidant effects. Modulates gene expression related to tissue repair. |
| Typical Dosage | CJC-1295 DAC: 1-2mg weekly. CJC-1295 no DAC (Mod GRF 1-29): 100-300mcg 2-3 times daily. | Topical: Applied as serum or cream 1-2 times daily. Injectable: 1-2mg daily for research purposes. Microneedling protocols often use 0.5-1%. |
| Administration | Subcutaneous injection, often combined with a GHRP like Ipamorelin for synergistic effects. Best administered before sleep or fasted. | Most commonly used topically for skin applications. Can be injected subcutaneously for systemic effects. Often combined with microneedling for enhanced skin penetration. |
| Side Effects | Water retention, tingling in extremities, potential increase in cortisol and prolactin levels. | Topical use is generally well-tolerated. May cause temporary skin irritation or redness in sensitive individuals. Injectable use may cause injection site reactions. |
| Best For |
What They Have in Common
Both CJC-1295 and GHK-Cu (Copper Peptide) are commonly used for: